Bengaluru, August 11, 2016: Granules India Ltd.(BSE: 532482, NSE: GRANULES), a growing pharmaceutical manufacturing company, announced today financial results for its first quarter ended 30th June, 2016.
The Company’s standalone sales during the quarter were Rs. 337 Cr., an increase of 4% from same quarter previous year. EBITDA and PAT increased by 16% and 17% to Rs. 76 Cr. and Rs. 36 Cr. compared to last year.
The Company’s Board of Directors has approved interim dividend of 20 paise per share of face value of Rs. 1 each.
Consolidated Q1FY17 Financial Results Highlights:-
Revenue: Rs. 344 Cr., an increase of 7% compared to Rs. 323 Cr. in Q1FY16
EBITDA: Rs. 72 Cr., an increase of 12% compared to Rs. 64 Cr. in Q1FY16
Operating Margin improved by 96 basis point to 20.8% from 19.9% in Q1FY16
Net Profit: Rs. 39 Cr., an increase of 37% compared to Rs. 29 Cr. in Q1FY16
Net Profit Margin improved by 249 basis point to 11.3% from 8.8% in Q1FY16
“Our top-line growth was slightly subdued but we have once again demonstrated our strength in operational excellence with improved bottom line. On business front, Granules Pharmaceuticals, Inc., our US based wholly owned subsidiary entered into an agreement with USpharma to acquire 12.5% of its stake. USpharma in collaboration with its manufacturing partners had submitted five ANDAs with Paragraph IV certifications, out of which four ANDAs have already been out licensed to us exclusively. These are in line with our organizational strategy of solidifying our presence in the US market and enhancing product portfolio by leveraging both internal and external product development capabilities.” said Krishna Prasad Chigurupati, Chairman & Managing Director.
Caution Statement:
Certain statements made above may be “forward looking statements” within the meaning of applicable laws and regulations.
Granules India Posts Net Profit of ₹ 37 Cr.
